Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine

Yasunori Watanabe; Luiza Mendonça; Elizabeth R. Allen; Andrew Howe; Mercede Lee; Joel D Allen; Himanshi Chawla; David Pulido; Francesca Donnellan; Hannah Davies; Marta Ulaszewska; Sandra Belij-Rammerstorfer; Susan Morris; Wanwisa Dejnirattisai; Juthathip Mongkolsapaya; Piyada Supasa; Gavin R. Screaton; Catherine M. Green; Teresa Lambe; Peijun Zhang; Sarah C Gilbert; Max Crispin.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-426463

Documentos relacionados

  1. Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine.
  2. Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.
  3. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.
  4. The Life of SARS-CoV-2 Inside Cells: Replication-Transcription Complex Assembly and Function.
  5. Circular RNA vaccines against SARS-CoV-2 and emerging variants.
  6. Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
  7. Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice.
  8. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
  9. SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity.
  10. Development of COVID-19 therapies: Nonclinical testing considerations.